Promising Developments in NMIBC

Experts on non–muscle invasive bladder cancer discuss promising developments in the overall treatment landscape, highlighting potentially practice-changing clinical research.

EP: 1.Navigating BCG Shortages in NMIBC

EP: 2.The Evolving Treatment Landscape in BCG-Unresponsive NMIBC

EP: 3.Efficacy and Safety Data from SunRISe-1

EP: 4.Overview of the QUILT Trial in BCG-Unresponsive NMIBC

EP: 5.Quality of Life and Progression Considerations in BCG-Unresponsive NMIBC

EP: 6.Adverse Effect Management and the Role of Immunotherapy in NMIBC

EP: 7.Selecting Optimal Treatment in BCG-Unresponsive NMIBC

EP: 8.Patient Monitoring Strategies in BCG-Unresponsive NMIBC

Now Viewing

EP: 9.Promising Developments in NMIBC

EP: 10.Key Takeaways on the Evolving NMIBC Treatment Landscape

Related Videos

Related Content

Advertisement

February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

Related Content

Advertisement

February 19th 2025

FDA approves expanded access program to provide alternative source of BCG

Hannah Clarke

According to ImmunityBio, shipments of rBCG are set to begin immediately via the EAP.

May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

February 17th 2025

Anktiva under review in UK for BCG-unresponsive NMIBC with CIS

Hannah Clarke

Anktiva is also currently under review for the CIS indication in the EU.

May 26th 2022

Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease

Urology Times staff

“We know that erectile dysfunction is really an important issue that can be a harbinger for other underlying cardiovascular or neurological health issues,” says Michael Lutz, MD.

February 15th 2025

Additional NIAGARA data spotlight benefits of durvalumab plus chemo for MIBC

Benjamin P. Saylor

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

February 15th 2025

Avelumab prolongs OS, PFS in advanced urothelial carcinoma irrespective of diabetes status

Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.